Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Preclinical studies show that opioids stimulate angiogenesis and tumor progression through the mu opioid receptor (MOR). Although MOR is overexpressed in several human malignancies, the effect of chronic opioid requirement on cancer progression or survival has not been examined in humans. METHODS: We performed a retrospective analysis on 113 patients identified in the Minneapolis VA Tumor Registry (test cohort) and 480 patients from the national VA Central Cancer Registry (validation cohort) who had been diagnosed with stage IV prostate cancer between 1995 and 2010 to examine whether MOR expression or opioid requirement is associated with disease progression and survival. All opioids were converted to oral morphine equivalents for comparison. Laser scanning confocal microscopy was used to analyze MOR immunoreactivity in prostate cancer biopsies. The effects of variables on outcomes were analyzed in univariable and multivariable models. RESULTS: In patients with metastatic prostate cancer, MOR expression and opioid requirement were independently associated with inferior progression‐free survival (hazard ratio [HR] 1.65, 95% confidence interval [CI] 1.33‐2.07, P<.001 and HR 1.08, 95% CI 1.03‐1.13, P<.001, respectively) and overall survival (HR 1.55, 95% CI 1.20‐1.99, P<.001 and HR 1.05, 95% CI 1.00‐1.10, P = .031, respectively). The validation cohort confirmed that increasing opioid requirement was associated with worse overall survival (HR 1.005, 95% CI 1.002‐1.008, P = .001). CONCLUSION: Higher MOR expression and greater opioid requirement are associated with shorter progression‐free survival and overall survival in patients with metastatic prostate cancer. Nevertheless, clinical practice should not be changed until prospective randomized trials show that opioid use is associated with inferior clinical outcomes, and that abrogation of the peripheral activities of opioids ameliorates this effect. Cancer 2013;119:4103–4110. ©2013 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 1×
“studies did not include an analysis of opioid requirement.(1,16,19,33,34) We have demonstrated that morphineinduced breast tumor growth in mice was accompanied”
BackgroundAbiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · cited 1×
“studies did not include an analysis of opioid requirement.(1,16,19,33,34) We have demonstrated that morphineinduced breast tumor growth in mice was accompanied”
Backgroundde Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318 · cited 1×
“studies did not include an analysis of opioid requirement.(1,16,19,33,34) We have demonstrated that morphineinduced breast tumor growth in mice was accompanied”
Background
Metadata
- Authors
- Zylla, D., Gourley, B. L., Vang, D., Jackson, S., Boatman, S., Lindgren, B., Kuskowski, M. A., Le, C., Gupta, K., & Gupta, P.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2013-09-16
- Volume
- 119
- Issue
- 23
- Pages
- 4103-4110
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1924169910
- Cited by
- 188
- References
- 3
- FWCI
- 9.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. https://app.cochat.ai/papers/10.1002/cncr.28345
- The paper
- Zylla, D., Gourley, B. L., Vang, D., Jackson, S., Boatman, S., Lindgren, B., Kuskowski, M. A., Le, C., Gupta, K., & Gupta, P. (2013). Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. Cancer. https://doi.org/10.1002/cncr.28345
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.